Kubota Pharmaceutical Holdings Co., Ltd.
KBBTF
Other OTC0.96
USD
- -
- -
ISIN
JP3266500002
Return %
Stock
S&P500
1Y
- -
17.85
3Y
- -
64.56
5Y
- -
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ryo Kubota
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Kasumigaseki Tokyu Building Tokyo Japan 100-0013
- IPO Date
- Jun 19, 2017
- Website
- kubotaholdings.co.jp
- Similar Companies
- Business
- Kubota Pharmaceutical Holdings Co., Ltd. develops and commercializes a portfolio of drugs and medical devices focused on ophthalmic disorders worldwide; core products and pipeline candidates include emixustat hydrochloride in Phase III for Stargardt disease and Phase II for proliferative diabetic retinopathy, Kubota Glass for myopia progression control, Lanosterol, Optogenetics therapies, and devices under the ZERO Diopter Project for pre-disease prevention and health management in ophthalmology. The Tokyo-based holding company, founded in 2002 and headquartered at 3-7-1 Kasumigaseki, Chiyoda-ku, operates through subsidiaries like Kubota Vision Inc., targeting markets in Japan, Asia, and globally with innovative therapeutics for vision preservation and restoration. Recent developments encompass sales and distribution agreements for Kubota Glass with Fuhao (China) Optical Technology Co., Ltd. and EverLight Instruments in 2024-2025, a basic agreement for capital and business partnership with Acrite CustIntCo Pte Ltd. in Singapore, debut of Kubota Glass at the ASEAN International Optics Fair Bangkok 2025, and large-scale exercises of stock acquisition rights.